Compare multi-agent consensus ratings, forecast paths, AI price targets, expected return, fundamentals, analyst disagreement, risks, and the investment thesis across short- and long-term horizons.

LLY.NYSE

Eli Lilly and

Healthcare | Drug Manufacturers - General

Global pharmaceutical company developing innovative medicines for diabetes, oncology, immunology, and neuroscience including breakthrough weight-loss drugs.

Flagship Insight

Why the Market Misprices the Massive Capital Intensity of Metabolic Blockbusters

High consensus across reports indicates that while metabolic franchise scaling drives unprecedented top-line velocity, massive capital expenditure and impending multiple compression will limit near-term equity returns. The primary driver is oral formulation commercialization, while the chief risk centers on regulatory pricing caps and margin dilution.

Forecast TimelineUpdated On Jul 02 2026

Eli Lilly and (LLY) Stock Forecast and AI Rating

Recommendation

Hold & Monitor

Model signals are balanced; wait for clearer evidence.

2027

1-Year

NEUTRAL

$1,305

+7.5%

+8.8% IF INCL. DIVS

2029

3-Year

N/A

$1,531

+30%

2031

5-Year

NEUTRAL

$1,789

+47%

+57% IF INCL. DIVS

LATEST DEEP FORECAST ANALYSIS BY iPULSE AI ENGINE | Jul 05, 2026

Visionary, Superintelligence, Insider, Strategist, Value Seeker, Vulture, Whistleblower, and more.

Elon Musk (Visionary), Superintelligence (Anthropologist), Machiavelli (Insider), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower).

Research support only. We don't give financial advice.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Grok

Investment Thesis Takeaway

Expert LanguageExpert Quant Language

Explained Simply

Interactive forecast chart

Expert Language

Explained Simply

The base-case consensus projects robust volumetric earnings expansion for this metabolic leader, offset by structural multiple compression as the asset transitions from hyper-growth to a mature, capital-intensive oligopoly. While the global commercialization of oral formulations dramatically expands the addressable market and bypasses sterile fill-finish bottlenecks, the massive physical capital intensity required to scale manufacturing and comply with domestic supply-chain mandates will temporarily suppress free cash flow conversion. Sophisticated investors must separate spectacular operational execution from equity performance, as high discount rates and competitive entry cap valuation multiples.

Key insights

Oral small-molecule commercialization bypasses sterile fill-finish bottlenecks, expanding global market penetration and primary care adoption.
Unprecedented capital expenditure builds an insurmountable physical manufacturing moat, locking out sub-scale biotech challengers.
Structural multiple compression from elevated levels toward historical industry norms acts as a persistent anchor on share price appreciation.
Impending price competition from well-capitalized peers and regulatory pricing frameworks will cap gross margin expansion over the horizon.
Fortress balance sheet strength and robust interest coverage provide absolute downside protection and strategic M&A optionality.
The core variant perception lies in the margin cannibalization of oral formats versus premium injectables.
High-density computational chemistry and AI integrations compress the R&D iteration loop, structurally lowering long-term drug discovery costs.

Preparing your access...

AI Consensus

AI Opinions

Company Profile

Eli Lilly and quarterly forecast scenarios

One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.

Quarterly Bear Case, Base Case, Bull Case, and S&P 500 benchmark forecasts for Eli Lilly and.
Quarter	Forecast date	Bear Case (USD)	Base Case (USD)	Bull Case (USD)	S&P 500 benchmark (USD)
Quarter 1+3M	Oct 02, 2026	$1,117	$1,225	$1,275	$736.09
Quarter 2+6M	Jan 02, 2027	$982.78	$1,239	$1,364	$724.14
Quarter 3+9M	Apr 02, 2027	$835.36	$1,229	$1,378	$713.57
Quarter 4+1Y	Jul 02, 2027	$751.83	$1,272	$1,447	$723.38
Quarter 5+15M	Oct 02, 2027	$691.68	$1,305	$1,514	$716.61
Quarter 6+18M	Jan 02, 2028	$657.10	$1,342	$1,590	$738.34
Quarter 7+21M	Apr 02, 2028	$617.67	$1,355	$1,702	$746.91
Quarter 8+2Y	Jul 02, 2028	$592.96	$1,371	$1,676	$771.93
Quarter 9+27M	Oct 02, 2028	$604.82	$1,379	$1,731	$782.73
Quarter 10+30M	Jan 02, 2029	$574.58	$1,427	$1,887	$807.31
Quarter 11+33M	Apr 02, 2029	$557.35	$1,461	$1,982	$822.72
Quarter 12+3Y	Jul 02, 2029	$579.64	$1,502	$2,061	$846.10
Quarter 13+39M	Oct 02, 2029	$591.23	$1,531	$2,123	$852.53
Quarter 14+42M	Jan 02, 2030	$579.41	$1,580	$2,271	$882.91
Quarter 15+45M	Apr 02, 2030	$596.79	$1,608	$2,158	$900.46
Quarter 16+4Y	Jul 02, 2030	$620.66	$1,617	$2,287	$922.67
Quarter 17+51M	Oct 02, 2030	$633.07	$1,648	$2,470	$935.91
Quarter 18+54M	Jan 02, 2031	$614.08	$1,692	$2,594	$952.30
Quarter 19+57M	Apr 02, 2031	$632.50	$1,741	$2,749	$976.28
Quarter 20+5Y	Jul 02, 2031	$645.15	$1,789	$2,942	$1,002

Alpha Gap and Advisor Disagreement

Alpha Gap

The core information gap lies in the market's mispricing of the asset's physical capital intensity and structural margin dynamics. While the crowd focuses on pristine accounting net income, a forensic look reveals massive cash absorption into working capital and factory buildouts. The market treats this as an asset-light technology platform, ignoring that scaling biological manufacturing requires heavy industrial capital. Furthermore, the crowd misprices the transition from premium injectables to cheaper oral small-molecules. While modeled as purely additive, the oral pill represents a structural deflationary force that will cannibalize high-margin injectables and compress blended average revenue per user. Finally, the market underappreciates the long-term threat of permanent gene-editing cures that could eventually displace chronic treatment models entirely.

Advisor Disagreement

The primary disagreement across reports centers on the financial impact of the oral formulation rollout. Some analyses view the oral pill as a highly profitable, additive volume driver that bypasses manufacturing bottlenecks and expands the addressable market. Conversely, other reports warn that the lower-priced oral format will aggressively cannibalize the high-margin injectable franchise, leading to severe margin dilution and a collapse in blended average revenue per user. There is also disagreement regarding the timing and severity of valuation multiple compression under the current high-rate monetary regime.

Financial Reviews by iPulse AI

Earnings and financials

The company is experiencing spectacular financial growth, highlighted by a massive surge in recent revenues and net income. This explosive performance is driven by the incredible global demand for its weight-loss and diabetes treatments. However, experts point out a key issue: the company's actual free cash flow is lagging behind its reported profits. This gap exists because a large amount of cash is currently tied up in building inventory and scaling up operations. While most assessments agree that the underlying business is highly profitable and acts as a great shield against inflation, they disagree on the future outlook. Some believe this hyper-growth will continue smoothly, while others warn that the introduction of cheaper daily pills will soon drag down overall profit margins and slow down revenue growth as the market becomes more crowded.

Profitability and margins

The company currently boasts outstanding profitability, with gross margins reaching eighty-four percent and operating margins expanding significantly. This software-like profitability reflects immense pricing power and the benefits of scaling up production. However, a major clash exists regarding whether these peak margins are sustainable. Some analysts believe the company can maintain these high margins by shifting to cheaper-to-make oral pills and bypassing traditional middlemen. In contrast, others argue that profit margins have reached their absolute peak and are bound to shrink. They point to upcoming price wars with major rivals, government price controls, and the lower selling price of the new daily pill as forces that will inevitably drag margins down. While the company remains a premier defensive asset, retail investors should expect profit margins to plateau or compress as the market matures.

Balance sheet and leverage

The company's balance sheet is an absolute fortress, offering incredible safety and financial firepower. With a massive pool of assets and highly manageable debt levels, the company is exceptionally well-positioned to survive any economic downturn or credit market squeeze. Its strong cash-generating power easily covers all interest payments, making it virtually immune to high interest rates. Analysts universally agree that this financial strength provides excellent downside protection for investors. It also gives management the flexibility to fund expensive research, build new factories, and acquire smaller biotech innovators without needing to borrow expensive money. There is very little disagreement here; the consensus is highly unified that the company's financial health is pristine, serving as a powerful shock absorber that allows the business to self-fund its ambitious global expansion plans.

Capex and investment intensity

The company is spending historic amounts of money on capital expenditures, dedicating billions to building advanced manufacturing plants. This heavy spending is highly expansionary, aimed at solving chronic supply shortages and constructing a massive physical shield against competitors. Because manufacturing complex weight-loss drugs is incredibly difficult, these factories create a powerful moat that smaller rivals simply cannot afford to replicate. Most assessments agree that this aggressive spending is a smart long-term move that strengthens the company's competitive position, especially as geopolitical rules push for domestic production. However, opinions differ on the near-term impact. Some analysts worry that this heavy spending will keep free cash flow depressed for years, while others expect a rapid payback as soon as these state-of-the-art facilities become fully operational and begin churning out high-volume oral treatments.